Clinical Trial Goal
To find out:
- The highest dose of HQP1351 that’s safe to give with or without blinatumomab
- If HQP1351 with or without blinatumomab is safe and works well to treat CML or Ph+ ALL
You may be able to join this trial if you:
- Are 18 years or older
- Have CML or PH+ ALL
- Do not have lymphoma in your brain or spinal cord
- Have not had an autologous (your own cells) or allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Blinatumomab is a bispecific T cell engager (BiTE) antibody that targets CD19 on certain cells.
HQP1351 is a tyrosine kinase inhibitor (TKI) that targets T315I in certain cells.
You’ll get treatment in cycles that last about 1 month. In each cycle, you'll get:
HQP1351 is a tyrosine kinase inhibitor (TKI) that targets T315I in certain cells.
You’ll get treatment in cycles that last about 1 month. In each cycle, you'll get:
- Blinatumomab – Given as intravenous (IV) infusions for 1 week
- HQP1351 – A pill that you take by mouth 1 time every other day
You'll have biopsies and/or scans to see how well the treatment is working.
The Food and Drug Administration (FDA) has not yet approved HQP1351.
Locations
Sponsors
lead: Ascentage Pharma Group Inc.
